- Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds
- Cold Plunge or Hot Bath? What’s Best for Ailing Muscles?
- Concussions Slow Brain Activity in High School Football Players
- Study Finds GLP-1 Meds Can Also Help the Kidneys
- Long COVID Brain Fog: Could the Lungs Hold Clues?
- Scientists Spot Gene That Could Help Cause Miscarriages
- Preschoolers’ Tantrums Can Be Early Sign of ADHD
- Mom’s Healthy Diet in Pregnancy Pays Big Dividends for Baby
- There’s a Best Option for Patients With Head-and-Neck Cancer Who Can’t Take Cisplatin
- Program Tripled Number of Completed At-Home Colon Cancer Tests
Chemo More Damaging to Hearts of Diabetics: Study
A small study finds that cancer patients who have diabetes may suffer worse heart damage from chemotherapy, potentially boosting their risk of heart failure.
There are increasing reports of toxic effects to the heart — also known as cardiotoxicity — due to chemotherapy with drugs known as anthracyclines, said study lead author Dr. Ana Catarina Gomes. Such drugs include doxorubicin (Doxil) and epirubicin (Ellence).
Gomes is a cardiologist in training at the Hospital Garcia de Orta in Almada, Portugal.
According to Gomes, this is “mainly because a smaller proportion of patients now die from cancer. In the coming years, this cardiotoxicity looks set to increase the burden of heart failure in cancer survivors.”
However, she said, “the good news is that cardiotoxicity can be reversible in the early stages before overt heart failure develops.”
The new study tracked 83 patients in a hospital surveillance program, including 54 with breast cancer, 20 with lymphoma and nine with gastric cancer. Their average age was 52, and 78 percent were female.
Patients with diabetes showed more signs of the damage that’s considered an early warning sign of heart failure. But the study did not prove that the blood sugar disease caused more damage from chemotherapy.
The findings were presented recently at the EuroEcho-Imaging meeting, in Leipzig, Germany.
“Cancer patients should strictly control cardiovascular risk factors with lifestyle changes and, if necessary, with medication,” Gomes said in a news release from the European Society of Cardiology. “But, of course, cardiovascular prevention should never postpone the beginning of chemotherapy, since treating cancer is the first priority.”
Research presented at meetings is considered preliminary until published in a peer-reviewed journal.
More information
For details on heart disease and cancer, visit the University of Texas MD Anderson Cancer Center.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.